Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

被引：28

作者：

Restellini, Sophie ^{[1
,2
]}

Afif, Waqqas ^{[1
]}

机构：

[1] McGill Univ, Hlth Ctr, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada

[2] Genevas Univ Hosp, Div Gastroenterol & Hepatol, CH-1205 Geneva, Switzerland

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期

关键词：

therapeutic drug monitoring; biologic; ustekinumab; vedolizumab; tofacitinib; ACTIVE ULCERATIVE-COLITIS; JANUS KINASE INHIBITOR; MAINTENANCE THERAPY; CROHNS-DISEASE; INDUCTION THERAPY; TROUGH CONCENTRATIONS; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ASSOCIATION; PHARMACOKINETICS;

D O I：

10.3390/jcm10061242

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.

引用

页码：1 / 16

页数：15

共 50 条

[1] Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease
Restellini, Sophie
Khanna, Reena
Afif, Waqqas
[J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2165 - 2172
[2] Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
Torres, N.
Martin Arranz, D.
Sanchez Azofra, M.
Martin Arranz, E.
Garcia, L.
Nozal, P.
Pascual, J.
Apraiz, I.
Lopez, M.
Arteta, D.
Nagore, D.
[J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S387 - S387
[3] Ustekinumab Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Saleh, Adam A.
Stading, Rachel
Miroballi, Natalia
Glassner, Kerri
Abraham, Bincy
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S636 - S637
[4] Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients on Vedolizumab
Ansari, Mohammed
Glassner, Kerri
Irani, Malcolm
Perry, Caroline
Abraham, Bincy P.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S435 - S436
[5] Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease.
Pugliese, Daniela
Privitera, Giuseppe
Pizzolante, Fabrizio
Gasbarrini, Antonio
Guidi, Luisa
Armuzzi, Alessandro
[J]. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2019, 65 (04) : 280 - 290
[6] Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab
Ansari, Mohammed
Glassner, Kerri
Irani, Malcolm
Saleh, Adam
Wang, Lin
Ezeana, Chika
Wong, Stephen
Perry, Caroline
Abraham, Bincy
[J]. JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (02) : 91 - 99
[7] Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease
Steenholdt, Casper
Lorentsen, Ruben Due
Petersen, Pernille Norgaard
Widigson, Ella S. K.
Kloft, Charlotte
Klaasen, Rolf Anton
Brynskov, Jorn
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1088 - 1098
[8] Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab
Saleh, Adam
Stading, Rachel
Miroballi, Natalia
Glassner, Kerri
Abraham, Bincy P.
[J]. JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (04) : 214 - 221
[9] Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Alsoud, Dahham
Vermeire, Severine
Verstockt, Bram
[J]. CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 17 - 30
[10] Early experience with therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease
Fernandez, R.
Sanchez, G.
Pedraza, L.
Prieto, V.
Calabuig, V. K.
Fernandez, E.
Otero, M. J.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 361 - 362

← 1 2 3 4 5 →